SYS-CON MEDIA Authors: Doug Masi, Mat Mathews, PR.com Newswire, David Smith, Tim Crawford

News Feed Item

HIV Vaccine Market Opportunity & Clinical Pipeline Analysis

DUBLIN, April 1, 2014 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/hnfpj3/hiv_vaccine) has announced the addition of the "HIV Vaccine Market Opportunity & Clinical Pipeline Analysis" report to their offering. 

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

Ever since HIV was identified as the cause for AIDS 30 years ago, the HIV virus has become one of the greatest challenges of public health facing all countries of the world. According to UNAIDS, death due to AIDS was estimated to close to 1.6 million in 2012. There were 2.3 million new HIV infections, and about 35.3 million people currently living with HIV. 

Given the pace at which the HIV virus is spreading, it is most likely that AIDS would take more lives than any other infectious disease in the future years to come. Inspite of well-expanded programs of prevention and treatment which are currently enabling the stakeholders to address the illness and death associated with HIV and AIDS, the HIV vaccines is considered to be the best solution to end this disease successfully.

HIV/AIDS has become of the leading infectious disease which is taking a huge death toll across the globe, even surpassing TB and malaria. Irrespective of whether the country is developed or developing, the disease is increasingly becoming prevalent, though with serious impact in the developing countries. 

It has been observed that almost nine out of every ten HIV infections are being diagnosed in the developing countries, and two-thirds are in Sub-Saharan Africa. India currently has close to 4 million infected people, which is the largest number of infected persons of any country in the world. Despite of the combating efforts, the Asian and other developing regions are increasingly feeling the heat as HIV continues to spread at a significant rate.

In recent years there have been significant breakthroughs achieved in terms of prevention and treatment of HIV/AIDS. The future is also likely to continue to witness similar technological and medical success in terms of new drugs and an efficient vaccine, with the help of adequate funding. 

Certain developments like a new treatment to reduce transmissibility in drug users and new efforts to strengthen the immune system have the potential to develop further and provide better healthcare services to the patients in the future.

Key Topics Covered: 

1. Introduction to HIV Vaccine & Mechanism
2. HIV Vaccine: Prevention & Cure
3. Why Need For HIV Vaccines?
4. Global HIV Vaccine Market Outlook
5. Research & Development Funding Scenario for HIV Vaccine
6. HIV Vaccine Market Dynamics
7. FDA Regulatory Framework for Development of HIV Vaccine
8. HIV Vaccine Clinical Trial by Phase & Country
9. Discontinued & Suspended HIV Vaccine Clinical Trial by Phase & Country
10. Competitive Landscape

Companies Mentioned: 

  • Antigen Express
  • Bionor Pharma
  • FIT Biotech
  • GenVec
  • GeoVax
  • Glaxo Smithkline
  • Immune Response BioPharma
  • Inovio Pharmaceuticals
  • Novartis
  • Sanofi Pasteur

For more information visit http://www.researchandmarkets.com/research/hnfpj3/hiv_vaccine

Media Contact: Laura Wood, +353-1-481-1716, [email protected]

SOURCE Research and Markets

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.